Healthcare Economics of High Frequency Spinal Cord Stimulation for Painful Diabetic Peripheral Neuropathy
Authors' conclusion
High frequency spinal cord stimulation significantly reduces total HCRU in patients with pDPN, and based on the average monthly cost reduction of $853, we estimate that the therapy recoups acquisition costs within 3.5 years. As policy increasingly focuses on value-based care, it will be critical to consider the cost and outcomes of innovative therapies.
Study context
- Population
- Patients with high-frequency spinal cord stimulation (HF-SCS) implantation January 2016–December 2019 with a diagnosis of diabetes or diabetic neuropathy within two years before implant
- Participants
- 132 patients
- Exposure
- Healthcare costs before vs after HF-SCS implantation
- Outcome
- Median total cost
- Follow-up
- Baseline (6 months pre-implant) and 1, 3 and 6 months post-implant
Methodological detailsclaims database (IBM MarketScan)
- Claims database (IBM MarketScan)
Main finding
As reported in the abstract
- Median total cost at baseline
- $19 220
- Median total cost at 1 month post-implant
- $1356
- Median total cost at 3 months post-implant
- $4858
- Median total cost at 6 months post-implant
- $13 305
- Average total cost reduction, baseline to 6 months post-implant (P < .001)
- $5118
- Average total cost reduction per month
- $853
Observational data: associations, not effects.
Further findings
Median out-of-pocket cost
- Median out-of-pocket cost at baseline
- $1477
- Median out-of-pocket cost at 6 months post-implant
- $710
Median device acquisition cost
- Median device acquisition cost
- $35 755
Safety
- Explant rate within six months
- 2.1%
Original publication
Healthcare Economics of High Frequency Spinal Cord Stimulation for Painful Diabetic Peripheral Neuropathy. J Diabetes Sci Technol. Published 31 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →